Metabolic & Obesity Deal Benchmarks
The GLP-1 and obesity licensing race is the hottest segment in biopharma. Benchmark deal terms across next-gen incretins, oral GLP-1s, NASH/MASH, and diabetes with $25B+ in verified metabolic deal value. Benchmarks derived from 74 verified transactions.
74
Total Deals
$652M
Avg Upfront
5
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
34
license
17
acquisition
14
collaboration
7
option
2
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
CSPC → AstraZeneca obesity and weight-related drug candidates | collaboration | $1.2B | $18.5B | Jun 2026 |
Renalys Pharma → Chugai Pharmaceutical Renalys renal disease program | acquisition | $98M | — | Jun 2026 |
Perfuse Therapeutics → Bayer Eye implant for glaucoma and diabetic retinopathy | acquisition | $300M | — | May 2026 |
Arthrosi Therapeutics → Sobi Arthrosi gout program | acquisition | $950M | $1.5B | May 2026 |
Siran Biotechnology → GSK siRNA obesity program | acquisition | $1.0B | $1.0B | May 2026 |
Perfuse Therapeutics → Bayer eye implant for glaucoma/diabetic retinopathy | acquisition | $300M | $2.5B | May 2026 |
Gan & Lee Pharmaceuticals → JW Pharmaceutical Bofanglutide Injection | license | $5M | $81M | Apr 2026 |
Insilico Medicine Inc. → Eli Lilly | collaboration | $115M | $2.9B | Mar 2026 |
YaoPharma → Pfizer YP05002 | license | $150M | $2.1B | Dec 2025 |
89bio → Roche Pegozafermin (MASH acquisition) | acquisition | $2.4B | $3.5B | Sep 2025 |
Benchmark Your Metabolic & Obesity Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 74 verified metabolic & obesity transactions.
Metabolic & Obesity Deal Benchmarking FAQ
How have GLP-1 deals reshaped metabolic deal benchmarks?
GLP-1 receptor agonist deals have dramatically raised metabolic deal valuations since 2023. Next-gen incretin deals (dual and triple agonists, oral formulations) now command upfronts of $100M-$500M+ with total deal values regularly exceeding $2B. The obesity market expansion has made metabolic deals among the most competitive in all of biopharma.
What are current deal terms for oral GLP-1 licensing agreements?
Oral GLP-1 licensing deals are commanding premium terms given the massive commercial opportunity of convenient dosing. Upfronts for clinical-stage oral GLP-1 assets range $200M-$500M+, with royalties of 15-25% reflecting the differentiated market position. Companies are competing aggressively for oral formulation technology platforms.
Are NASH/MASH deal terms recovering after clinical setbacks?
NASH/MASH deal activity has stabilized following the FDA approval of resmetirom in 2024. New deals are increasingly structured with risk-sharing milestones tied to histological endpoints. Upfronts have moderated ($30M-$100M for Phase 2 assets) but total deal values remain substantial given the large addressable liver disease market.